Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HENRIK BO ILLUM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1982805164
CMS profile
818448
Location
BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HENRIK BO ILLUM

NPI 1982805164 · CMS profile ID 818448

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BEDFORD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HENRIK BO ILLUM, NPI 1982805164, CMS profile ID 818448, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1982805164?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845874393 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $218.19 5
PY2021 $11.92 1
PY2022 $388.68 8
PY2023 $308.84 15
PY2024 $466.63 22
PY2025 $915.63 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,785.70 23
PY2024 Principal investigator $56,382.74 49
PY2023 Principal investigator $148,965.97 74
PY2022 Principal investigator $217,097.35 91
PY2021 Principal investigator $222,524.42 113
PY2020 Principal investigator $248,821.20 67
PY2019 Recipient $1,250.00 1
PY2019 Principal investigator $428,314.17 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,253.00 12/19/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017240539
Principal investigator 1 MorphoSys AG $476.00 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336457
Principal investigator 1 MorphoSys AG $125.00 12/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336459
Principal investigator 1 MorphoSys AG $125.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336453
Principal investigator 1 MorphoSys AG $476.00 11/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336455
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $714.00 10/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027455229
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $714.00 10/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1027455243
Principal investigator 1 MorphoSys AG $941.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336125
Principal investigator 1 MorphoSys AG $125.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336449
Principal investigator 1 MorphoSys AG $956.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336451
Principal investigator 1 Novocure Inc. $850.00 10/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1023008871
Principal investigator 1 MorphoSys AG $861.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336123
Principal investigator 1 MorphoSys AG $200.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336437
Principal investigator 1 MorphoSys AG $1,600.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336439
Principal investigator 1 MorphoSys AG $125.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336441
Principal investigator 1 MorphoSys AG $1,600.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336443
Principal investigator 1 MorphoSys AG $1,600.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336445
Principal investigator 1 MorphoSys AG $1,600.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336447
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,120.00 09/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA - SOUTHWEST FT WORTH
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017217191
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,124.75 08/08/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA - SOUTHWEST FT WORTH
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1017213811
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336425
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336429
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336431
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336433
Principal investigator 1 MorphoSys AG $956.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336435
Principal investigator 1 Novocure Inc. $850.00 07/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1023008779
Principal investigator 1 MorphoSys AG $125.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336421
Principal investigator 1 MorphoSys AG $476.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336423
Principal investigator 1 MorphoSys AG $200.00 06/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336427
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,478.70 06/06/2023 Non-covered Recipient Entity
Us Oncology Research Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen No dispute reported 06/30/2026 1027477310
Principal investigator 1 MorphoSys AG $200.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336119
Principal investigator 1 MorphoSys AG $656.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336121
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336399
Principal investigator 1 MorphoSys AG $125.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336403
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336405
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336407
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336409
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336411
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336415
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336417
Principal investigator 1 MorphoSys AG $1,600.00 05/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336419
Principal investigator 1 MorphoSys AG $200.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336117
Principal investigator 1 MorphoSys AG $200.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336395
Principal investigator 1 MorphoSys AG $956.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336397
Principal investigator 1 MorphoSys AG $200.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336401
Principal investigator 1 Novocure Inc. $850.00 04/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1023008701
Principal investigator 1 Celgene Corporation $714.00 03/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488925
Principal investigator 1 MorphoSys AG $901.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336115
Principal investigator 1 MorphoSys AG $125.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336391
Principal investigator 1 MorphoSys AG $200.00 03/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336393
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,100.00 03/08/2023 Non-covered Recipient Entity
Us Oncology Res Llc
Phase II/III 1L MSS CRC Nivo+ SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer No dispute reported 06/30/2026 1027476345
Principal investigator 1 MorphoSys AG $2,081.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336113
Principal investigator 1 MorphoSys AG $1,600.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336375
Principal investigator 1 MorphoSys AG $125.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336379
Principal investigator 1 MorphoSys AG $1,600.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336381
Principal investigator 1 MorphoSys AG $250.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336383
Principal investigator 1 MorphoSys AG $1,600.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336385
Principal investigator 1 MorphoSys AG $1,600.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336387
Principal investigator 1 MorphoSys AG $842.00 02/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336389
Principal investigator 1 Acerta Pharma LLC $3,750.00 02/10/2023 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 991127843
Principal investigator 1 Eli Lilly and Company $168.05 02/08/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1038144571
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,708.47 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 991128279
Principal investigator 1 Celgene Corporation $1,428.00 01/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488945
Principal investigator 1 Celgene Corporation $1,428.00 01/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect MM- The Multiple Myeloma Disease Registry No dispute reported 06/30/2026 1026488969
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,870.00 01/15/2023 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Phase II/III 1L MSS CRC Nivo+ SOC vs SOC - An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer No dispute reported 06/30/2026 1027474067
Principal investigator 1 MorphoSys AG $476.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336111
Principal investigator 1 MorphoSys AG $956.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336367
Principal investigator 1 MorphoSys AG $125.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336371
Principal investigator 1 MorphoSys AG $125.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336373
Principal investigator 1 MorphoSys AG $842.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 1060336377
Principal investigator 1 Novartis Pharmaceuticals Corporation $63.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY PA - SOUTHWEST FT WORTH
A randomized double blind placebo controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer who received no prior hormonal therapy for advanced disease No dispute reported 06/30/2026 1017216279
Principal investigator 1 Novocure Inc. $850.00 01/15/2023 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1023008617
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,400.00 01/05/2023 Non-covered Recipient Entity
Us Oncology
Phase IIA CTLA4 NF Randomized chemo combo study in mCRPC - A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1027458055
Principal investigator 1 Novartis Pharmaceuticals Corporation $780.00 01/05/2023 Non-covered Recipient Entity
US ONCOLOGY RESEARCH
A randomized double blind placebo controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer who received no prior hormonal therapy for advanced disease No dispute reported 06/30/2026 1017240773